Preclinical cancer biotech Arvinas files for a $100 million IPO
Arvinas, a preclinical biotech developing protein therapies for metastatic cancers, filed on Thursday with the SEC to raise up to $100 million in an initial public offering.
The New Haven, CT-based company was founded in 2013 and booked $12 million in revenue for the 12 months ended June 30, 2018. It plans to list on the Nasdaq under the symbol ARVN. Arvinas filed confidentially on June 22, 2018. Goldman Sachs, Citi and Piper Jaffray are the joint bookrunners on the deal. No pricing terms were disclosed.
The article Preclinical cancer biotech Arvinas files for a $100 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.